BPC-157 (Body Protection Compound-157) is the most widely used regenerative peptide. This protocol covers the practical framework for different injury types — musculoskeletal, gastrointestinal, and systemic healing applications.

Dose selection

Standard dose: 250–500 mcg per day

Conservative start: 250 mcg daily for the first week, increasing to 500 mcg if well-tolerated and healing progress is insufficient

Aggressive protocol: 250 mcg twice daily (morning + evening) = 500 mcg total. Split dosing maintains more consistent systemic levels but requires two injections per day

Body weight does not significantly influence BPC-157 dosing in practice. The 250–500 mcg range covers the effective window across body sizes based on available animal data scaled to human equivalents.

Route and injection site strategy

For musculoskeletal injuries (tendon, ligament, muscle, joint)

Route: Subcutaneous injection

Site: As close to the injury as anatomically practical. BPC-157's mechanism involves local upregulation of GH receptors, VEGFR2, and NO signaling — proximity to the target tissue matters.

Practical injection site mapping:

Achilles tendon: Posterior ankle, 1–2 cm above the calcaneal insertion
Patellar tendon: Inferior pole of the patella
Rotator cuff: Lateral deltoid/supraspinatus area
Tennis elbow: Lateral epicondyle region
Low back: Paraspinal area nearest to the pain source

If local injection is technically difficult or uncomfortable, abdominal subcutaneous injection provides systemic delivery. Evidence for local vs. systemic efficacy in humans is absent — the local approach is based on biological rationale, not clinical comparison data.

For gastrointestinal healing (gut inflammation, ulcers, leaky gut)

Route: Oral (capsule or liquid)

Dose: 250–500 mcg, taken on an empty stomach

Rationale: BPC-157 is a fragment of a gastric juice protein (BPC) and demonstrates remarkable stability in gastric acid. Oral administration delivers the peptide directly to the GI mucosa. Preclinical data shows oral BPC-157 protects against NSAID-induced ulcers, alcohol-induced gastric damage, and inflammatory bowel injury.

For systemic or non-localized conditions

Route: Subcutaneous, abdominal

Dose: 250–500 mcg daily

Cycle structure

Standard cycle: 4–8 weeks

Assessment point: Week 4. Evaluate whether subjective and objective markers have improved. If progress is evident but incomplete, extend to 8 weeks. If no progress at all, reassess the diagnosis.

Rest period: 2–4 weeks between cycles if a second cycle is planned

Maximum continuous use: 8 weeks. While BPC-157 does not appear to cause receptor desensitization in the same way GH secretagogues do, periodic cycling is standard practice in the absence of long-term human safety data.

Combination with TB-500

The BPC-157 + TB-500 "healing stack" is the most common peptide combination for injury recovery.

Rationale: Mechanistic complementarity:

BPC-157 → local vascular growth (VEGFR2), GH receptor upregulation, NO modulation
TB-500 → systemic cell migration (actin sequestration), neovascularization, anti-inflammatory

Stack protocol:

BPC-157: 250–500 mcg daily (subcutaneous, near injury)
TB-500: Loading — 2–5 mg twice weekly for 2 weeks; Maintenance — 2 mg weekly for remaining cycle
Duration: 6–8 weeks combined

Timing considerations

Time of day: No strong evidence for morning vs. evening superiority. Consistency matters more than timing.
Relation to meals: Injectable — no meal timing requirement. Oral — take on an empty stomach (30+ minutes before food).
Relation to exercise: Some practitioners inject post-training near the affected area, reasoning that the exercise-induced inflammatory response creates a signaling environment that BPC-157 can modulate. This is logical but unproven.

Monitoring milestones

Week 1–2:

Reduced local inflammation (swelling, warmth)
Pain at rest should decrease
No objective tissue change expected yet

Week 3–4:

Improved range of motion
Reduced pain during activity
Functional milestones: increased tolerance for rehabilitation exercises

Week 5–8:

Progressive strength recovery
Imaging improvement if tracked (ultrasound echogenicity, MRI signal)
Rehabilitation intensity should be advancing

When to reassess

No subjective improvement by week 4 → re-evaluate diagnosis
Worsening symptoms → discontinue and investigate (missed structural pathology?)
GI symptoms on injectable BPC-157 → rare; reduce dose or switch to oral
Injection site lump or persistent redness → rotate sites; ensure proper subcutaneous technique